UBS Group AG Has $3.45 Million Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT

UBS Group AG lowered its stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 46.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 188,651 shares of the company’s stock after selling 161,513 shares during the period. UBS Group AG’s holdings in Eyepoint Pharmaceuticals were worth $3,447,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Eyepoint Pharmaceuticals by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock valued at $88,100,000 after buying an additional 1,027,623 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Eyepoint Pharmaceuticals by 33.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,490 shares of the company’s stock valued at $539,000 after buying an additional 7,408 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after buying an additional 1,358 shares during the last quarter. Aberdeen Group plc grew its stake in Eyepoint Pharmaceuticals by 101.6% in the 4th quarter. Aberdeen Group plc now owns 1,605,984 shares of the company’s stock valued at $29,341,000 after buying an additional 809,182 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Eyepoint Pharmaceuticals by 31.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 42,655 shares of the company’s stock valued at $779,000 after buying an additional 10,155 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Insider Buying and Selling at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 2,437 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $36,555.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.46% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $12.93 on Monday. The company has a market capitalization of $1.08 billion, a P/E ratio of -3.69 and a beta of 1.76. Eyepoint Pharmaceuticals, Inc. has a 12-month low of $5.45 and a 12-month high of $19.11. The firm has a 50-day moving average price of $13.46 and a two-hundred day moving average price of $14.68.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. Equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.16 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on EYPT shares. HC Wainwright boosted their price objective on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Royal Bank Of Canada cut their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Chardan Capital boosted their price objective on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Citigroup boosted their price objective on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a report on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $31.80.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.